Medical Oncologist

  • |

    Dr Sam Khan

    Dr Sam Khan Organisation: University Hospitals of LeicesterJob title: Associate Professor & Honorary Consultant Medical Oncologist Dr Sam Khan has been an honorary Consultant Medical Oncologist at the University Hospitals of Leicester and Associate Professor of Medical Oncology at the University of Leicester since 2024. She qualified at Manchester Medical School in 2010, and undertook…

  • |

    Dr Sean Dulloo

    Dr Sean Dulloo MBBS, MSc, MD (Res), FRCP (London) Organisation: University Hospitals of Leicester, Leicester NHS Trust and University of LeicesterJob title: Consultant Medical Oncology & Head of Service, Clinic Lead (Thoracic Oncology) Dr Sean Dulloo is a Consultant Medical Oncologist & Honorary Associate Professor at the University Hospitals of Leicester NHS Trust and University…

  • |

    Dr Meera Chauhan

    Dr Meera Chauhan Organisation: University Hospitals of LeicesterJob title: Consultant Medical Oncologist & Oncology Block Lead Dr Meera Chauhan is a Consultant Medical Oncologist at the University Hospitals of Leicester NHS trust, specialising in the treatment of thoracic malignancies, including lung cancer and mesothelioma. She holds a PhD in Cancer Studies and is the Immunotherapy…

  • |

    Professor Samreen Ahmed

    Professor Samreen Ahmed Organisation: University Hospitals of LeicesterJob title: Chair of Thoracic Medical Oncology & Director, Mesothelioma Research Programme Consultant Medical Oncologist University Hospitals of Leicester NHS Trust Professor Ahmed has been a Consultant in Medical Oncology since 2006. She has a research degree (MD) through Nottingham University and received an Honorary Chair in 2016…

  • |

    Professor Dean Fennell

    Professor Dean Fennell Organisation: University Hospitals of LeicesterJob title: Chair of Thoracic Medical Oncology & Director, Mesothelioma Research Programme Professor Dean Fennell is a physician scientist focused on advancing stratified therapy and immuno-oncology for patients with mesothelioma. He has designed and led several investigator-initiated trials from phase 1 through phase III (including NERO, CONFIRM, VIM,…